MGMT and glioblastoma: Here, we report the safety and efficacy results of a phase Ib/II dose-escalation study of pamiparib in combination with RT and/or TMZ in patients with treatment-naïve, MGMT-unmethylated glioblastoma and recurrent/refractory glioblastoma with unmethylated or methylated MGMT (NCT03150862 and EudraCT 2017-001554-33).